Nektar Therapeutics (NKTR) Competitors

$68.43 -2.19 (-3.10%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$68.26 -0.17 (-0.25%)

As of 05/18/2026 06:19 PM Eastern

NKTR vs. CORT, SUPN, PRGO, OMER, and PCRX

Should you buy Nektar Therapeutics stock or one of its competitors? MarketBeat compares Nektar Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nektar Therapeutics include Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Perrigo (PRGO), Omeros (OMER), and Pacira BioSciences (PCRX). These companies are all part of the "pharmaceuticals" industry.

How does Nektar Therapeutics compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Nektar Therapeutics (NASDAQ:NKTR) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

In the previous week, Nektar Therapeutics had 13 more articles in the media than Corcept Therapeutics. MarketBeat recorded 16 mentions for Nektar Therapeutics and 3 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 0.85 beat Nektar Therapeutics' score of 0.69 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Corcept Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

Corcept Therapeutics has a net margin of 6.14% compared to Nektar Therapeutics' net margin of -284.18%. Corcept Therapeutics' return on equity of 7.40% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.14%	7.40%	5.76%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

Corcept Therapeutics has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	7.77	$99.65M	$0.35	157.49
Nektar Therapeutics	$55.23M	41.87	-$164.08M	-$8.42	N/A

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Corcept Therapeutics currently has a consensus price target of $70.83, indicating a potential upside of 28.51%. Nektar Therapeutics has a consensus price target of $149.63, indicating a potential upside of 118.65%. Given Nektar Therapeutics' higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Corcept Therapeutics beats Nektar Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Nektar Therapeutics compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Nektar Therapeutics (NASDAQ:NKTR) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Supernus Pharmaceuticals has a net margin of -3.74% compared to Nektar Therapeutics' net margin of -284.18%. Supernus Pharmaceuticals' return on equity of 13.07% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

Supernus Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

75.9% of Nektar Therapeutics shares are owned by institutional investors. 8.8% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Supernus Pharmaceuticals currently has a consensus target price of $62.17, indicating a potential upside of 28.63%. Nektar Therapeutics has a consensus target price of $149.63, indicating a potential upside of 118.65%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Supernus Pharmaceuticals has higher revenue and earnings than Nektar Therapeutics. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.90	-$38.55M	-$0.51	N/A
Nektar Therapeutics	$55.23M	41.87	-$164.08M	-$8.42	N/A

In the previous week, Nektar Therapeutics had 12 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 16 mentions for Nektar Therapeutics and 4 mentions for Supernus Pharmaceuticals. Nektar Therapeutics' average media sentiment score of 0.69 beat Supernus Pharmaceuticals' score of 0.53 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Nektar Therapeutics beats Supernus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to Perrigo?

Nektar Therapeutics (NASDAQ:NKTR) and Perrigo (NYSE:PRGO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by insiders. Comparatively, 0.4% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Nektar Therapeutics has higher earnings, but lower revenue than Perrigo. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	41.87	-$164.08M	-$8.42	N/A
Perrigo	$4.25B	0.35	-$1.43B	-$13.10	N/A

Nektar Therapeutics currently has a consensus price target of $149.63, indicating a potential upside of 118.65%. Perrigo has a consensus price target of $19.33, indicating a potential upside of 80.77%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Perrigo has a net margin of -43.50% compared to Nektar Therapeutics' net margin of -284.18%. Perrigo's return on equity of 9.96% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-284.18%	-85.40%	-39.99%
Perrigo	-43.50%	9.96%	3.90%

Nektar Therapeutics has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Perrigo has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

In the previous week, Nektar Therapeutics had 15 more articles in the media than Perrigo. MarketBeat recorded 16 mentions for Nektar Therapeutics and 1 mentions for Perrigo. Perrigo's average media sentiment score of 0.84 beat Nektar Therapeutics' score of 0.69 indicating that Perrigo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Perrigo	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Nektar Therapeutics beats Perrigo on 9 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to Omeros?

Omeros (NASDAQ:OMER) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

48.8% of Omeros shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 12.9% of Omeros shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Nektar Therapeutics had 6 more articles in the media than Omeros. MarketBeat recorded 16 mentions for Nektar Therapeutics and 10 mentions for Omeros. Nektar Therapeutics' average media sentiment score of 0.69 beat Omeros' score of 0.53 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Omeros has a beta of 2.66, meaning that its share price is 166% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Omeros currently has a consensus target price of $40.33, suggesting a potential upside of 244.73%. Nektar Therapeutics has a consensus target price of $149.63, suggesting a potential upside of 118.65%. Given Omeros' stronger consensus rating and higher possible upside, analysts clearly believe Omeros is more favorable than Nektar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -284.18%. Nektar Therapeutics' return on equity of -85.40% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

Omeros has higher earnings, but lower revenue than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$0.70	16.71
Nektar Therapeutics	$55.23M	41.87	-$164.08M	-$8.42	N/A

Summary

Omeros beats Nektar Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to Pacira BioSciences?

Nektar Therapeutics (NASDAQ:NKTR) and Pacira BioSciences (NASDAQ:PCRX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

In the previous week, Nektar Therapeutics had 9 more articles in the media than Pacira BioSciences. MarketBeat recorded 16 mentions for Nektar Therapeutics and 7 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.81 beat Nektar Therapeutics' score of 0.69 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Pacira BioSciences	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacira BioSciences has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	41.87	-$164.08M	-$8.42	N/A
Pacira BioSciences	$726.41M	1.22	$7.03M	$0.12	187.00

Pacira BioSciences has a net margin of 0.70% compared to Nektar Therapeutics' net margin of -284.18%. Pacira BioSciences' return on equity of 10.24% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-284.18%	-85.40%	-39.99%
Pacira BioSciences	0.70%	10.24%	5.47%

Nektar Therapeutics has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Nektar Therapeutics presently has a consensus price target of $149.63, suggesting a potential upside of 118.65%. Pacira BioSciences has a consensus price target of $29.40, suggesting a potential upside of 31.02%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Nektar Therapeutics is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Pacira BioSciences beats Nektar Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Nektar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKTR vs. The Competition

Export

Metric	Nektar Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.39B	$3.00B	$6.25B	$12.29B
Dividend Yield	N/A	1.98%	2.80%	5.30%
P/E Ratio	-8.13	17.22	20.86	25.23
Price / Sales	41.87	275.32	549.93	74.46
Price / Cash	N/A	56.35	27.48	37.30
Price / Book	15.52	3.93	9.67	6.63
Net Income	-$164.08M	$74.99M	$3.56B	$335.59M
7 Day Performance	-12.75%	-4.47%	-1.70%	-1.20%
1 Month Performance	-19.36%	-7.93%	-2.66%	-1.16%
1 Year Performance	556.40%	29.34%	30.03%	28.10%

Nektar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NKTR Nektar Therapeutics	3.0195 of 5 stars	$68.43 -3.1%	$149.63 +118.7%	+566.0%	$2.39B	$55.23M	N/A	220	Analyst Upgrade
CORT Corcept Therapeutics	4.2055 of 5 stars	$57.91 +13.2%	$70.83 +22.3%	-26.6%	$6.21B	$761.41M	165.35	300
SUPN Supernus Pharmaceuticals	3.1134 of 5 stars	$51.25 +1.4%	$62.17 +21.3%	+44.6%	$2.97B	$718.95M	N/A	580
PRGO Perrigo	4.4901 of 5 stars	$10.96 -1.4%	$19.33 +76.4%	-60.4%	$1.52B	$4.25B	N/A	8,100
OMER Omeros	3.8538 of 5 stars	$14.68 -0.6%	$40.33 +174.8%	+264.5%	$1.06B	N/A	N/A	210	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NKTR) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nektar Therapeutics (NKTR) Competitors

NKTR vs. CORT, SUPN, PRGO, OMER, and PCRX

How does Nektar Therapeutics compare to Corcept Therapeutics?

Summary

How does Nektar Therapeutics compare to Supernus Pharmaceuticals?

Summary

How does Nektar Therapeutics compare to Perrigo?

Summary

How does Nektar Therapeutics compare to Omeros?

Summary

How does Nektar Therapeutics compare to Pacira BioSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR vs. The Competition

Nektar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nektar Therapeutics (NKTR) Competitors

NKTR vs. CORT, SUPN, PRGO, OMER, and PCRX

How does Nektar Therapeutics compare to Corcept Therapeutics?

Does the media favor CORT or NKTR?

Which has more risk and volatility, CORT or NKTR?

Is CORT or NKTR more profitable?

Which has stronger valuation & earnings, CORT or NKTR?

Do insiders & institutionals believe in CORT or NKTR?

Do analysts recommend CORT or NKTR?

Summary

How does Nektar Therapeutics compare to Supernus Pharmaceuticals?

Is SUPN or NKTR more profitable?

Which has more risk and volatility, SUPN or NKTR?

Do institutionals and insiders believe in SUPN or NKTR?

Do analysts prefer SUPN or NKTR?

Which has preferable earnings & valuation, SUPN or NKTR?

Does the media prefer SUPN or NKTR?

Summary

How does Nektar Therapeutics compare to Perrigo?

Do insiders and institutionals have more ownership in NKTR or PRGO?

Which has preferable earnings and valuation, NKTR or PRGO?

Do analysts recommend NKTR or PRGO?

Is NKTR or PRGO more profitable?

Which has more risk & volatility, NKTR or PRGO?

Does the media favor NKTR or PRGO?

Summary

How does Nektar Therapeutics compare to Omeros?

Do institutionals and insiders have more ownership in OMER or NKTR?

Does the media prefer OMER or NKTR?

Which has more volatility & risk, OMER or NKTR?

Do analysts rate OMER or NKTR?

Is OMER or NKTR more profitable?

Which has better earnings and valuation, OMER or NKTR?

Summary

How does Nektar Therapeutics compare to Pacira BioSciences?

Does the media refer more to NKTR or PCRX?

Which has higher earnings and valuation, NKTR or PCRX?

Is NKTR or PCRX more profitable?

Which has more volatility & risk, NKTR or PCRX?

Do insiders and institutionals hold more shares of NKTR or PCRX?

Do analysts rate NKTR or PCRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR vs. The Competition

Nektar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools